The role of ADHD genetic risk in mid-to-late life somatic health conditionsShow others and affiliations
2022 (English)In: Translational Psychiatry, E-ISSN 2158-3188, Vol. 12, no 1, article id 152Article in journal (Refereed) Published
Abstract [en]
Growing evidence suggests that ADHD, an early onset neurodevelopmental disorder, is associated with poor somatic health in adulthood. However, the mechanisms underlying these associations are poorly understood. Here, we tested whether ADHD polygenic risk scores (PRS) are associated with mid-to-late life somatic health in a general population sample. Furthermore, we explored whether potential associations were moderated and mediated by life-course risk factors. We derived ADHD-PRS in 10,645 Swedish twins born between 1911 and 1958. Sixteen cardiometabolic, autoimmune/inflammatory, and neurological health conditions were evaluated using self-report (age range at measure 42-88 years) and clinical diagnoses defined by International Classification of Diseases codes in national registers. We estimated associations of ADHD-PRS with somatic outcomes using generalized estimating equations, and tested moderation and mediation of these associations by four life-course risk factors (education level, body mass index [BMI], tobacco use, alcohol misuse). Results showed that higher ADHD-PRS were associated with increased risk of seven somatic outcomes (heart failure, cerebro- and peripheral vascular disease, obesity, type 1 diabetes, rheumatoid arthritis, and migraine) with odds ratios ranging 1.07 to 1.20. We observed significant mediation effects by education, BMI, tobacco use, and alcohol misuse, primarily for associations of ADHD-PRS with cardiometabolic outcomes. No moderation effects survived multiple testing correction. Our findings suggests that higher ADHD genetic liability confers a modest risk increase for several somatic health problems in mid-to-late life, particularly in the cardiometabolic domain. These associations were observable in the general population, even in the absence of medical treatment for ADHD, and appear to be in part mediated by life-course risk factors.
Place, publisher, year, edition, pages
Nature Publishing Group, 2022. Vol. 12, no 1, article id 152
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:oru:diva-98538DOI: 10.1038/s41398-022-01919-9ISI: 000779948000001PubMedID: 35399118Scopus ID: 2-s2.0-85127839227OAI: oai:DiVA.org:oru-98538DiVA, id: diva2:1651404
Funder
European Commission, 728018 965381The Swedish Brain Foundation, FO2021-0115Swedish Research Council, 2018-02599 2017-00641Swedish Society for Medical Research (SSMF), PD20-0036Forte, Swedish Research Council for Health, Working Life and Welfare, 2019-01172
Note
Funding agencies:
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Institute of Mental Health (NIMH) R21MH116188
Estonian Research Council PSG615
Correction: The role of ADHD genetic risk in mid-to-late life somatic health conditions. Garcia-Argibay, M., du Rietz, E., Lu, Y. et al. Transl Psychiatry 12, 166 (2022). https://doi.org/10.1038/s41398-022-01933-x
2022-04-122022-04-122024-01-17Bibliographically approved